Nilo Therapeutics

Nilo Therapeutics is a New York-based biotechnology company developing a new class of medicines that target the brain-body neural circuits regulating the immune system. Building on discoveries that identified specific vagal neurons controlling systemic inflammation, Nilo aims to restore immune homeostasis centrally rather than broadly suppress the immune system, offering a differentiated approach to treating autoimmune and inflammatory disease. The company launched out of stealth in October 2025 with a $101 million Series A.